There are currently no treatment options for infection with Rift Valley fever virus (RVFV). Here, Chapman et al., show that a combination of human monoclonal antibodies targeting two different steps in early virus cell entry enhances protection in a mouse model and is effective at low doses.
- Nathaniel S. Chapman
- Ruben J. G. Hulswit
- James E. Crowe Jr.
